TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
To the OMX
Investor News No. 02-07 / Copenhagen, 11 October 2007
TopoTarget strengthens sales and marketing organisation
Copenhagen, Denmark - 11 October 2007 - TopoTarget A/S (OMX:TOPO) has announced
the further strengthening of its sales and marketing organisation following
the launch of Savene™ and Totect™ on the European and US markets in 2006 and
2007 respectively.
From today, John Parsons is appointed Chief Commercial Officer, with
responsibility for developing TopoTarget's sales and marketing efforts in both
Europe and the US. John joined the company in 2006 and has been instrumental in
building up the sales force in the US and has been integral in the structuring
of TopoTarget's ongoing sales effort in Europe. John has over 30 years
commercial experience in building marketing and sales infrastructures for both
pharmaceutical and biotech companies.
“I am proud that TopoTarget has such an experienced and talented team with a
comprehensive range of expertise in our different operational areas. John
Parson's new role enables us to strengthen our global market focus and allows
us to optimise our opportunities in sales and marketing so that we can continue
to build a business providing value for patients and stakeholders,” said Peter
Buhl Jensen, CEO of TopoTarget.
Today's announcement does not change TopoTarget's full-year financial guidance
for 2007.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Ulla Hald Buhl Mobile +45 21 70 10 49
Director of IR and Communications
Background information
About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in US, Switzerland, Germany and the UK, dedicated to finding
''Answers for cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and eight drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is
TopoTarget's first product on the market. For more information, please refer to
www.topotarget.com.
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
